191 related articles for article (PubMed ID: 36964259)
1. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
2. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
3. Complement inhibitors for age-related macular degeneration.
Tzoumas N; Riding G; Williams MA; Steel DH
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
[TBL] [Abstract][Full Text] [Related]
4. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Khanani AM; Patel SS; Staurenghi G; Tadayoni R; Danzig CJ; Eichenbaum DA; Hsu J; Wykoff CC; Heier JS; Lally DR; Monés J; Nielsen JS; Sheth VS; Kaiser PK; Clark J; Zhu L; Patel H; Tang J; Desai D; Jaffe GJ;
Lancet; 2023 Oct; 402(10411):1449-1458. PubMed ID: 37696275
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
7. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
9. Two studies to learn if avacincaptad pegol works and is safe in people with geographic atrophy: a plain language summary of the GATHER1 and GATHER 2 studies.
Jaffe GJ; Khanani AM
Immunotherapy; 2024 Mar; 16(4):205-221. PubMed ID: 38270081
[TBL] [Abstract][Full Text] [Related]
10. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials.
Danzig CJ; Khanani AM; Kaiser PK; Chang MA; Kovach JL; Lally DR; Rachitskaya A; Sheth VS; Vajzovic L; Clark J; Tang J; Zhu L; Desai D; Chakravarthy U
Ophthalmol Retina; 2024 May; ():. PubMed ID: 38719191
[TBL] [Abstract][Full Text] [Related]
11. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
12. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
13. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
[TBL] [Abstract][Full Text] [Related]
14. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
[TBL] [Abstract][Full Text] [Related]
15. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 Trial Evaluating Minocycline for Geographic Atrophy in Age-Related Macular Degeneration: A Nonrandomized Controlled Trial.
Keenan TDL; Bailey C; Abraham M; Orndahl C; Menezes S; Bellur S; Arunachalam T; Kangale-Whitney C; Srinivas S; Karamat A; Nittala M; Cunningham D; Jeffrey BG; Wiley HE; Thavikulwat AT; Sadda S; Cukras CA; Chew EY; Wong WT
JAMA Ophthalmol; 2024 Apr; 142(4):345-355. PubMed ID: 38483382
[TBL] [Abstract][Full Text] [Related]
17. Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.
Kim BJ; Hunter A; Brucker AJ; Hahn P; Gehrs K; Patel A; Edwards AO; Li Y; Khurana RN; Nissim I; Daniel E; Grunwald J; Ying GS; Pistilli M; Maguire MG; Dunaief JL
Ophthalmol Retina; 2020 Sep; 4(9):889-898. PubMed ID: 32418846
[TBL] [Abstract][Full Text] [Related]
18. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
19. The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review and meta-analysis.
Garg A; Nanji K; Tai F; Phillips M; Zeraatkar D; Garg SJ; Sadda SR; Kaiser PK; Guymer RH; Sivaprasad S; Wykoff CC; Chaudhary V
Surv Ophthalmol; 2024; 69(3):349-361. PubMed ID: 38008405
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Blue Fundus Autofluorescence and SD-OCT Measurements of Geographic Atrophy in Dry Age-Related Macular Degeneration.
Ehlers JP; McConville C; Yordi S; Cetin H; Cakir Y; Kalra G; Amine R; Whitney J; Whitmore V; Bonnay M; Reese J; Clark J; Zhu L; Luo D; Jaffe GJ; Srivastava SK
Am J Ophthalmol; 2024 May; 266():92-101. PubMed ID: 38719131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
